These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 19486571

  • 1. Treatment induced leucopenia in hepatitis C and Role of G-CSF in its management.
    Shafi MS, Sheikh NI, Rizvi F, Afzal M, Manzoor S.
    J Coll Physicians Surg Pak; 2009 Jun; 19(6):346-9. PubMed ID: 19486571
    [Abstract] [Full Text] [Related]

  • 2. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin.
    Gopal DV, Rabkin JM, Berk BS, Corless CL, Chou S, Olyaei A, Orloff SL, Rosen HR.
    Liver Transpl; 2001 Mar; 7(3):181-90. PubMed ID: 11244158
    [Abstract] [Full Text] [Related]

  • 3. Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation.
    Tandon P, Doucette K, Fassbender K, Vandermeer B, Durec T, Dryden DM.
    J Viral Hepat; 2011 Jul; 18(7):e381-93. PubMed ID: 21692951
    [Abstract] [Full Text] [Related]

  • 4. Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist.
    Tajuddin T, Ryan EJ, Norris S, Hegarty JE, O'Farrelly C.
    J Gastroenterol Hepatol; 2010 Dec; 25(12):1883-90. PubMed ID: 21092001
    [Abstract] [Full Text] [Related]

  • 5. Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.
    Koskinas J, Zacharakis G, Sidiropoulos J, Elefsiniotis J, Savvas S, Kotsiou S, Kountouras D, Schina M, Kostopoulos P, Archimandritis A.
    J Med Virol; 2009 May; 81(5):848-52. PubMed ID: 19319942
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.
    Koirala J, Gandotra SD, Rao S, Sangwan G, Mushtaq A, Htwe TH, Adamski A, Blessman D, Khardori NM.
    J Viral Hepat; 2007 Nov; 14(11):782-7. PubMed ID: 17927614
    [Abstract] [Full Text] [Related]

  • 9. Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon-alpha treated chronic hepatitis C patients with declining leukocyte counts.
    Durante-Mangoni E, Iardino P, Utili R, Adinolfi LE, Ruggiero G.
    Antivir Ther; 2006 Nov; 11(5):637-40. PubMed ID: 16964833
    [Abstract] [Full Text] [Related]

  • 10. Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C.
    Liu YL, Du XF, Chen XY, Ma LN, Guo DD, Lu JF, Cao ZH, Zhang YH.
    Scand J Infect Dis; 2013 Dec; 45(12):939-43. PubMed ID: 24090457
    [Abstract] [Full Text] [Related]

  • 11. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.
    Mac Nicholas R, Norris S.
    Aliment Pharmacol Ther; 2010 May; 31(9):929-37. PubMed ID: 20175767
    [Abstract] [Full Text] [Related]

  • 12. Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin.
    Pau AK, McLaughlin MM, Hu Z, Agyemang AF, Polis MA, Kottilil S.
    AIDS Patient Care STDS; 2006 Sep; 20(9):612-9. PubMed ID: 16987047
    [Abstract] [Full Text] [Related]

  • 13. Leucopenia is a side effect of combination therapy for hepatitis C infection.
    Russo F, Bacosi M, Miglioresi L, Ricci GL.
    Am J Gastroenterol; 2000 Apr; 95(4):1100-1. PubMed ID: 10763981
    [No Abstract] [Full Text] [Related]

  • 14. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Horváth G, Tolvaj G, Halász T, Stotz G.
    Orv Hetil; 2007 Aug 19; 148(33):1545-50. PubMed ID: 17686672
    [Abstract] [Full Text] [Related]

  • 15. Role of epoetin alfa in maintaining ribavirin dose.
    Afdhal NH.
    Gastroenterol Clin North Am; 2004 Mar 19; 33(1 Suppl):S25-35. PubMed ID: 15081101
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
    Seydi M, Morlat P, Bonnet F, Rambeloarisoa J, Bernard N, Lacoste D, Bonarek M, Trimoulet P, Ramanampamonjy R, Lafon ME, Dramé M, Beylot J.
    Rev Med Interne; 2005 Apr 19; 26(4):280-7. PubMed ID: 15820563
    [Abstract] [Full Text] [Related]

  • 17. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
    Berardi S, Lodato F, Gramenzi A, D'Errico A, Lenzi M, Bontadini A, Morelli MC, Tamè MR, Piscaglia F, Biselli M, Sama C, Mazzella G, Pinna AD, Grazi G, Bernardi M, Andreone P.
    Gut; 2007 Feb 19; 56(2):237-42. PubMed ID: 16798778
    [Abstract] [Full Text] [Related]

  • 18. Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C.
    Li Z, Zhang Y, An J, Feng Y, Deng H, Xiao S, Ji F.
    J Clin Virol; 2014 Jul 19; 60(3):190-5. PubMed ID: 24830933
    [Abstract] [Full Text] [Related]

  • 19. Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy.
    Nadeem A, Hussain MM, Aslam M, Hussain T, Butt IF, Ali Khan S, Asad A.
    J Ayub Med Coll Abbottabad; 2009 Jul 19; 21(2):103-6. PubMed ID: 20524482
    [Abstract] [Full Text] [Related]

  • 20. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Halász T, Farkas A, Tolvaj G, Horváth G.
    Orv Hetil; 2006 Feb 19; 147(7):321-4. PubMed ID: 17489160
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.